Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Anna Sureda, Christian Chabannon, Tamás Masszi, David Pohlreich, Christof Scheid, Catherine Thieblemont, Björn E. Wahlin, Ioanna Sakellari, Nigel Russell, Andrea Janikova, Anna Dabrowska-Iwanicka, Cyrille Touzeau, Albert Esquirol, Esa Jantunen, Steffie van der Werf, Paul Bosman, Ariane Boumendil, Qianying Liu, Marina Celanovic, Silvia MontotoPeter Dreger

Research output: Contribution to journalArticle

Abstract

Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.

Original languageEnglish
JournalBone Marrow Transplantation
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Granulocyte Colony-Stimulating Factor
Registries
Lymphoma
Transplantation
Bone Marrow
Disease-Free Survival
Drug Therapy
Propensity Score
Survival
JM 3100
Hematopoietic Stem Cell Mobilization
Recurrence
Incidence
Hematopoietic Stem Cells
Confidence Intervals

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. / Sureda, Anna; Chabannon, Christian; Masszi, Tamás; Pohlreich, David; Scheid, Christof; Thieblemont, Catherine; Wahlin, Björn E.; Sakellari, Ioanna; Russell, Nigel; Janikova, Andrea; Dabrowska-Iwanicka, Anna; Touzeau, Cyrille; Esquirol, Albert; Jantunen, Esa; van der Werf, Steffie; Bosman, Paul; Boumendil, Ariane; Liu, Qianying; Celanovic, Marina; Montoto, Silvia; Dreger, Peter.

In: Bone Marrow Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

Sureda, A, Chabannon, C, Masszi, T, Pohlreich, D, Scheid, C, Thieblemont, C, Wahlin, BE, Sakellari, I, Russell, N, Janikova, A, Dabrowska-Iwanicka, A, Touzeau, C, Esquirol, A, Jantunen, E, van der Werf, S, Bosman, P, Boumendil, A, Liu, Q, Celanovic, M, Montoto, S & Dreger, P 2019, 'Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor', Bone Marrow Transplantation. https://doi.org/10.1038/s41409-019-0693-z
Sureda, Anna ; Chabannon, Christian ; Masszi, Tamás ; Pohlreich, David ; Scheid, Christof ; Thieblemont, Catherine ; Wahlin, Björn E. ; Sakellari, Ioanna ; Russell, Nigel ; Janikova, Andrea ; Dabrowska-Iwanicka, Anna ; Touzeau, Cyrille ; Esquirol, Albert ; Jantunen, Esa ; van der Werf, Steffie ; Bosman, Paul ; Boumendil, Ariane ; Liu, Qianying ; Celanovic, Marina ; Montoto, Silvia ; Dreger, Peter. / Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor. In: Bone Marrow Transplantation. 2019.
@article{a17a2949485f4d3998c8d061a7fee792,
title = "Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor",
abstract = "Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3{\%}) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.",
author = "Anna Sureda and Christian Chabannon and Tam{\'a}s Masszi and David Pohlreich and Christof Scheid and Catherine Thieblemont and Wahlin, {Bj{\"o}rn E.} and Ioanna Sakellari and Nigel Russell and Andrea Janikova and Anna Dabrowska-Iwanicka and Cyrille Touzeau and Albert Esquirol and Esa Jantunen and {van der Werf}, Steffie and Paul Bosman and Ariane Boumendil and Qianying Liu and Marina Celanovic and Silvia Montoto and Peter Dreger",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41409-019-0693-z",
language = "English",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

AU - Sureda, Anna

AU - Chabannon, Christian

AU - Masszi, Tamás

AU - Pohlreich, David

AU - Scheid, Christof

AU - Thieblemont, Catherine

AU - Wahlin, Björn E.

AU - Sakellari, Ioanna

AU - Russell, Nigel

AU - Janikova, Andrea

AU - Dabrowska-Iwanicka, Anna

AU - Touzeau, Cyrille

AU - Esquirol, Albert

AU - Jantunen, Esa

AU - van der Werf, Steffie

AU - Bosman, Paul

AU - Boumendil, Ariane

AU - Liu, Qianying

AU - Celanovic, Marina

AU - Montoto, Silvia

AU - Dreger, Peter

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.

AB - Plerixafor + granulocyte-colony stimulating factor (G-CSF) is administered to patients with lymphoma who are poor mobilizers of hematopoietic stem cells (HSCs) in Europe. This international, multicenter, non-interventional registry study (NCT01362972) evaluated long-term follow-up of patients with lymphoma who received plerixafor for HSC mobilization versus other mobilization methods. Propensity score matching was conducted to balance baseline characteristics between comparison groups. The following mobilization regimens were compared: G-CSF + plerixafor (G + P) versus G-CSF alone; G + P versus G-CSF + chemotherapy (G + C); and G-CSF + plerixafor + chemotherapy (G + P + C) versus G + C. The primary outcomes were progression-free survival (PFS), overall survival (OS), and cumulative incidence of relapse (CIR). Overall, 313/3749 (8.3%) eligible patients were mobilized with plerixafor-containing regimens. After propensity score matching, 70 versus 36 patients were matched in the G + P versus G-CSF alone cohort, 124 versus 124 in the G + P versus G + C cohort, and 130 versus 130 in the G + P + C versus G + C cohort. For both PFS and OS, the upper bound of confidence interval for the hazard ratio was >1.3 for all comparisons, implying that non-inferiority was not demonstrated. No major differences in PFS, OS, and CIR were observed between the plerixafor and comparison groups.

UR - http://www.scopus.com/inward/record.url?scp=85074477601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074477601&partnerID=8YFLogxK

U2 - 10.1038/s41409-019-0693-z

DO - 10.1038/s41409-019-0693-z

M3 - Article

C2 - 31570781

AN - SCOPUS:85074477601

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

ER -